MAINTENANCE – The infectiologist and hospital practitioner at Cochin Hospital Odile Launay is the first signatory of a study carried out by the AP-HP and published in the New England Journal of Medicine which compares the effectiveness of vaccines from GSK-Sanofi and that from Pfizer/BioNTech when used as a booster. And draws possible lessons for the rest of the vaccination campaigns.
LE FIGARO. – What products have you tested?
Odile LAUNAY. – We compared the Pfizer/BioNTech vaccine, already on the market, with two Sanofi-GSK products currently being validated by health authorities. This is a more traditional technology than messenger RNA, known as “recombinant proteins”. To sum up, Sanofi produces virus spikes in bioreactors (the proteins that form small spikes on its surface, Editor’s note) which will serve as training targets for the immune system. And to stimulate the body’s response and recruit immune cells to the injection site, the company combines them with an adjuvant produced by its partner GSK. Sanofi has produced two types of spikes: those of the original Wuhan virus, and those of the Beta variant (originally called “South African variant”). This gives rise to two separate vaccines, one containing only “Wuhan” spikes and the other a mixture of the spikes of the two variants.
What tests have you…
This article is for subscribers only. You have 77% left to discover.
Pushing back the limits of science is also freedom.
Keep reading your article for €0.99 for the first month
Already subscribed? Login